JP2008535903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535903A5 JP2008535903A5 JP2008505966A JP2008505966A JP2008535903A5 JP 2008535903 A5 JP2008535903 A5 JP 2008535903A5 JP 2008505966 A JP2008505966 A JP 2008505966A JP 2008505966 A JP2008505966 A JP 2008505966A JP 2008535903 A5 JP2008535903 A5 JP 2008535903A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- optionally substituted
- treatment
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000005505 thiomorpholino group Chemical group 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67188605P | 2005-04-15 | 2005-04-15 | |
| US67183005P | 2005-04-15 | 2005-04-15 | |
| GB0507831A GB0507831D0 (en) | 2005-04-18 | 2005-04-18 | DNA-PK inhibitors |
| US69606405P | 2005-07-01 | 2005-07-01 | |
| US71890405P | 2005-09-20 | 2005-09-20 | |
| PCT/GB2006/001379 WO2006109084A1 (en) | 2005-04-15 | 2006-04-13 | Dna-pk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535903A JP2008535903A (ja) | 2008-09-04 |
| JP2008535903A5 true JP2008535903A5 (enExample) | 2009-04-30 |
Family
ID=36579227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505964A Pending JP2008535902A (ja) | 2005-04-15 | 2006-04-13 | Ｄｎａ−ｐｋ阻害剤 |
| JP2008505966A Pending JP2008535903A (ja) | 2005-04-15 | 2006-04-13 | Ｄｎａ−ｐｋ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505964A Pending JP2008535902A (ja) | 2005-04-15 | 2006-04-13 | Ｄｎａ−ｐｋ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060264623A1 (enExample) |
| EP (2) | EP1869040A1 (enExample) |
| JP (2) | JP2008535902A (enExample) |
| KR (1) | KR20080002963A (enExample) |
| AR (2) | AR054438A1 (enExample) |
| AU (1) | AU2006235731A1 (enExample) |
| CA (1) | CA2603637A1 (enExample) |
| IL (1) | IL186445A0 (enExample) |
| MX (1) | MX2007012696A (enExample) |
| NO (1) | NO20075809L (enExample) |
| TW (2) | TW200720274A (enExample) |
| UY (1) | UY29479A1 (enExample) |
| WO (2) | WO2006109081A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| US7429660B2 (en) * | 2003-08-13 | 2008-09-30 | Kudos Pharmaceuticals Limited | ATM inhibitors |
| KR20070059156A (ko) * | 2004-09-20 | 2007-06-11 | 쿠도스 파마슈티칼스 리미티드 | Ｄｎａ－ｐｋ 억제제 |
| WO2006085067A1 (en) * | 2005-02-09 | 2006-08-17 | Kudos Pharmaceuticals Limited | Atm inhibitors |
| AR054438A1 (es) * | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
| UY31232A1 (es) * | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
| EP2198710A1 (de) | 2008-12-19 | 2010-06-23 | Bayer CropScience AG | Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze |
| WO2010136778A1 (en) * | 2009-05-29 | 2010-12-02 | Kudos Pharmaceuticals Limited | Dibenzothiophene derivatives as dna- pk inhibitors |
| WO2011001114A1 (fr) | 2009-07-02 | 2011-01-06 | Sanofi-Aventis | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| RU2561130C2 (ru) * | 2009-07-02 | 2015-08-20 | Санофи | НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ |
| FR2947551B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| FR2951170B1 (fr) * | 2009-10-09 | 2011-12-02 | Sanofi Aventis | Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| FR2947548B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| JP5663571B2 (ja) | 2009-07-02 | 2015-02-04 | サノフイ | 新規２，３−ジヒドロ−１Ｈ−イミダゾ｛１，２−ａ｝ピリミジン−５−オン誘導体、これらの調製およびこれらの薬学的使用 |
| EP2448932B1 (fr) | 2009-07-02 | 2014-03-05 | Sanofi | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4-(3h)-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| FR2947550B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| CN102858528B (zh) | 2010-04-15 | 2016-05-11 | 3M创新有限公司 | 包括光学活性区域和光学非活性区域的回射制品 |
| US20130109687A1 (en) * | 2010-04-30 | 2013-05-02 | Gary J. Nabel | Methods of treating hiv infection: inhibition of dna dependent protein kinase |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| PL2658844T3 (pl) | 2010-12-28 | 2017-04-28 | Sanofi | Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) |
| US8530470B2 (en) * | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
| HUE054031T2 (hu) | 2012-04-24 | 2021-08-30 | Vertex Pharma | DNS-PK inhibitorok |
| ES2637829T3 (es) * | 2012-06-15 | 2017-10-17 | Basf Se | Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados |
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| RU2676259C2 (ru) | 2013-03-12 | 2018-12-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
| JP6784942B2 (ja) * | 2014-12-02 | 2020-11-18 | オールテリティ セラピューティクス リミテッド | ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物 |
| AU2017335648B2 (en) | 2016-09-27 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| CN109232476B (zh) * | 2018-11-06 | 2020-06-26 | 常州大学 | 一种制备n-苯基-3-吗啡啉丙酰胺的方法 |
| US20230111712A1 (en) * | 2020-03-13 | 2023-04-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stable reactive compositions for bioconjugation, probes, and protein labeling |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1303724A (enExample) | 1969-05-14 | 1973-01-17 | ||
| JPH0753725B2 (ja) | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| JPH04502322A (ja) | 1988-12-21 | 1992-04-23 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
| US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| JPH03215423A (ja) | 1990-01-18 | 1991-09-20 | Kyowa Hakko Kogyo Co Ltd | 血管拡張剤 |
| CA2081577A1 (en) | 1990-06-20 | 1991-12-21 | Ronald B. Gammill | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones |
| US5252735A (en) | 1990-06-29 | 1993-10-12 | The Upjohn Company | Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones |
| US5302613A (en) | 1990-06-29 | 1994-04-12 | The Upjohn Company | Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones |
| DK0489877T3 (da) | 1990-06-29 | 1996-02-05 | Upjohn Co | Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner |
| WO1994005283A1 (fr) | 1992-09-02 | 1994-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Medicament anti-vih |
| CA2159192C (en) * | 1993-04-09 | 2006-07-25 | Keiichi Tanaka | Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases |
| US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| US5441947A (en) | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
| US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
| US5504103A (en) | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
| CA2133815A1 (en) | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
| US6632789B1 (en) | 1994-04-29 | 2003-10-14 | The United States Of America As Represented By The Secretary Of The Navy | Methods for modulating T cell responses by manipulating intracellular signal transduction |
| US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
| GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| AU1461197A (en) | 1995-11-16 | 1997-06-05 | Icos Corporation | Cell cycle checkpoint pik-related kinase materials and methods |
| GB2302021A (en) | 1996-10-16 | 1997-01-08 | Lilly Co Eli | Inhibiting bone loss or resorption |
| CA2292540A1 (en) | 1997-06-06 | 1998-12-10 | Jann N. Sarkaria | Screening for phosphatidylinositol related-kinase inhibitors |
| AU8068198A (en) | 1997-06-13 | 1998-12-30 | President And Fellows Of Harvard College | Methods for treating human cancers |
| FR2776291B1 (fr) | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
| US6387640B1 (en) * | 1999-02-10 | 2002-05-14 | St. Jude Children's Research Hospital | ATM kinase modulation for screening and therapies |
| US6348311B1 (en) | 1999-02-10 | 2002-02-19 | St. Jude Childre's Research Hospital | ATM kinase modulation for screening and therapies |
| US6333180B1 (en) * | 1999-12-21 | 2001-12-25 | International Flavors & Fragrances Inc. | Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate |
| AU2001230426C1 (en) * | 2000-01-24 | 2006-06-22 | Astrazeneca Ab | Therapeutic morpholino-substituted compounds |
| EP1299101A4 (en) * | 2000-06-28 | 2004-06-16 | Teva Pharma | CARVEDILOL |
| EP1351946A2 (en) | 2000-09-01 | 2003-10-15 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| EP1353693B1 (en) | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
| GB0119863D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| US6908932B2 (en) | 2001-10-24 | 2005-06-21 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| AU2002357667A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| US7049313B2 (en) | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| NZ534821A (en) | 2002-02-25 | 2006-07-28 | Kudos Pharm Ltd | Pyranones useful as ATM inhibitors |
| WO2003093261A1 (en) | 2002-04-30 | 2003-11-13 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7429660B2 (en) | 2003-08-13 | 2008-09-30 | Kudos Pharmaceuticals Limited | ATM inhibitors |
| KR20070059156A (ko) * | 2004-09-20 | 2007-06-11 | 쿠도스 파마슈티칼스 리미티드 | Ｄｎａ－ｐｋ 억제제 |
| WO2006085067A1 (en) | 2005-02-09 | 2006-08-17 | Kudos Pharmaceuticals Limited | Atm inhibitors |
| AR054438A1 (es) | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
| UY31232A1 (es) | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones |
-
2006
- 2006-04-12 AR ARP060101479A patent/AR054438A1/es not_active Application Discontinuation
- 2006-04-12 AR ARP060101480A patent/AR053358A1/es not_active Application Discontinuation
- 2006-04-13 JP JP2008505964A patent/JP2008535902A/ja active Pending
- 2006-04-13 EP EP06726777A patent/EP1869040A1/en not_active Withdrawn
- 2006-04-13 US US11/403,763 patent/US20060264623A1/en not_active Abandoned
- 2006-04-13 JP JP2008505966A patent/JP2008535903A/ja active Pending
- 2006-04-13 MX MX2007012696A patent/MX2007012696A/es not_active Application Discontinuation
- 2006-04-13 AU AU2006235731A patent/AU2006235731A1/en not_active Abandoned
- 2006-04-13 WO PCT/GB2006/001369 patent/WO2006109081A1/en not_active Ceased
- 2006-04-13 CA CA002603637A patent/CA2603637A1/en not_active Abandoned
- 2006-04-13 EP EP06726768A patent/EP1869021A1/en not_active Withdrawn
- 2006-04-13 US US11/403,606 patent/US7696203B2/en not_active Expired - Fee Related
- 2006-04-13 KR KR1020077026502A patent/KR20080002963A/ko not_active Withdrawn
- 2006-04-13 WO PCT/GB2006/001379 patent/WO2006109084A1/en not_active Ceased
- 2006-04-14 TW TW095113561A patent/TW200720274A/zh unknown
- 2006-04-14 TW TW095113560A patent/TW200720271A/zh unknown
- 2006-04-18 UY UY29479A patent/UY29479A1/es not_active Application Discontinuation
-
2007
- 2007-10-07 IL IL186445A patent/IL186445A0/en unknown
- 2007-11-12 NO NO20075809A patent/NO20075809L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535903A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| AU2023201821B2 (en) | Modulators of the integrated stress pathway | |
| RU2448096C2 (ru) | Диарилгидантоины | |
| US11040035B2 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| JP2011509949A5 (enExample) | ||
| JP2011526917A5 (enExample) | ||
| CN114174303B (zh) | 作为sting激动剂的大环化合物及其方法和用途 | |
| JP2013510120A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2014528467A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2008526999A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2012505234A5 (enExample) |